Prasad Raju, an officer at CRISPR Therapeutics AG, has sold 79,393 shares of the company in a transaction valued at approximately $3.96 million. This sale, reported in a recent SEC filing, is significant as it reflects Raju's ongoing engagement with the company while also managing his equity stake.

The sale was executed on November 6, 2026, and was made possible through a stock option exercise. Raju acquired the shares through various transactions over the years, including restricted stock grants. The filing indicates that he had acquired 64,578 shares as part of this exercise, with the remaining shares coming from previous stock transactions.

Background

CRISPR Therapeutics AG, identified by the Central Index Key (CIK) 0001674416, operates in the biological products sector, specifically focusing on innovative therapies. The company is incorporated in Zug, Switzerland, and trades on the NASDAQ under the ticker symbol CRSP. Recent filings include a Form 144 submitted on November 6, 2026, and multiple Form 4 filings throughout 2026, indicating ongoing activity in the company's stock.

What the Filing Says

The SEC filing confirms that Raju sold 79,393 shares with an aggregate market value of $3,960,183.20. The filing states, "The nature of acquisition transaction was a stock option exercise," indicating a structured approach to managing his holdings. Raju's involvement with CRISPR Therapeutics continues to be significant, as he has been acquiring shares through various methods, including restricted stock grants.

Impact

This transaction may affect various stakeholders, including shareholders and potential investors in CRISPR Therapeutics AG. Raju's sale of shares could be seen as a signal of confidence in the company's future, even as he liquidates a portion of his holdings. The biological products industry, particularly in the realm of gene editing and therapy, may also respond to such high-profile transactions as they reflect the ongoing trends in corporate governance and executive compensation.

What's Next

The filing does not say what happens next. However, Raju's ongoing activity with CRISPR Therapeutics suggests that he remains committed to the company's mission and future endeavors.